1. Home
  2. SSL vs BLCO Comparison

SSL vs BLCO Comparison

Compare SSL & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sasol Ltd.

SSL

Sasol Ltd.

HOLD

Current Price

$12.71

Market Cap

5.6B

Sector

Energy

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$15.48

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSL
BLCO
Founded
1950
1853
Country
South Africa
Canada
Employees
27411
N/A
Industry
Oil & Gas Production
Ophthalmic Goods
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SSL
BLCO
Price
$12.71
$15.48
Analyst Decision
Sell
Buy
Analyst Count
1
12
Target Price
N/A
$18.55
AVG Volume (30 Days)
2.9M
380.7K
Earning Date
04-17-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
N/A
$8.63
Revenue Next Year
$4.48
$5.58
P/E Ratio
$13.51
N/A
Revenue Growth
N/A
6.47
52 Week Low
$2.78
$10.45
52 Week High
$13.02
$18.92

Technical Indicators

Market Signals
Indicator
SSL
BLCO
Relative Strength Index (RSI) 78.11 34.23
Support Level $6.09 $14.39
Resistance Level N/A $17.66
Average True Range (ATR) 0.42 0.49
MACD 0.09 -0.12
Stochastic Oscillator 91.55 1.16

Price Performance

Historical Comparison
SSL
BLCO

About SSL Sasol Ltd.

Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: